Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights
Authors
Keywords
-
Journal
Cancer Management and Research
Volume Volume 14, Issue -, Pages 1043-1061
Publisher
Informa UK Limited
Online
2022-03-07
DOI
10.2147/cmar.s267260
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2
- (2021) Kim A. Reiss et al. JOURNAL OF CLINICAL ONCOLOGY
- LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer
- (2021) Lena Seifert et al. Cancers
- The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer
- (2021) William A. Freed-Pastor et al. CANCER CELL
- Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis
- (2021) Raffaella Casolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Masitinib plus gemcitabine as first-line treatment of pancreatic cancer with pain: Results from phase 3 study AB12005.
- (2021) Joel Ezenfis et al. JOURNAL OF CLINICAL ONCOLOGY
- High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach.
- (2021) Andreas Seeber et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.
- (2021) Osama E. Rahma et al. JOURNAL OF CLINICAL ONCOLOGY
- Trial in progress: Open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.
- (2021) Tara Elisabeth Seery et al. JOURNAL OF CLINICAL ONCOLOGY
- Sindilimab combined with nab-paclitaxel plus gemcitabine as first-line treatment for patients with advanced pancreatic cancer.
- (2021) Huayun Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2 study of cyclophosphamide (CY), GVAX, pembrolizumab (Pembro), and stereotactic body radiation (SBRT) in patients (pts) with locally advanced pancreas cancer (LAPC).
- (2021) Valerie Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
- (2021) Peter Grell et al. JOURNAL OF CLINICAL ONCOLOGY
- Camrelizumab combined with ablation and chemotherapy for pancreatic cancer with liver metastases: A single-arm, phase II, prospective clinical study.
- (2021) Zhiwei Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Toripalimab with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a single-arm, open-label, phase Ib/II clinical study.
- (2021) Ke Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
- (2021) Gang Jin et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results.
- (2021) Mark H. O'Hara et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma
- (2021) Felix Popp et al. Cancers
- Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?
- (2021) Liyang Fei et al. Frontiers in Immunology
- MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes
- (2020) Christoph Fraune et al. ANNALS OF SURGICAL ONCOLOGY
- Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA).
- (2020) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society
- (2020) Takuji Okusaka et al. PANCREAS
- Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
- (2020) Praveen Vikas et al. Frontiers in Oncology
- The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis
- (2020) Saber Amin et al. BMC CANCER
- Immunotherapy for pancreatic cancer: A 2020 update
- (2020) Dimitrios Schizas et al. CANCER TREATMENT REVIEWS
- Targeting focal adhesion kinase in cancer cells and the tumor microenvironment
- (2020) James M. Murphy et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality
- (2020) Xiaohan Zhou et al. Frontiers in Oncology
- Progress of immune checkpoint LAG‑3 in immunotherapy (Review)
- (2020) Chanchan Shan et al. Oncology Letters
- A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
- (2020) D Brock Hewitt et al. ANNALS OF SURGERY
- An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer
- (2019) Steven Feins et al. AMERICAN JOURNAL OF HEMATOLOGY
- A randomized Phase 2b study of GVAX pancreas and CRS-207 compared to chemotherapy in previously-treated metastatic pancreatic adenocarcinoma patients (ECLIPSE Study)
- (2019) Dung T. Le et al. CLINICAL CANCER RESEARCH
- Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
- (2019) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).
- (2019) Philippe Alexandre Cassier et al. JOURNAL OF CLINICAL ONCOLOGY
- A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
- (2019) Frans V. Suurs et al. PHARMACOLOGY & THERAPEUTICS
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
- (2018) Zishuo I. Hu et al. CLINICAL CANCER RESEARCH
- Satellite DNA evolution: old ideas, new approaches
- (2018) Sarah Sander Lower et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
- (2018) Gregory L. Beatty et al. GASTROENTEROLOGY
- The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis
- (2018) He-Li Gao et al. Hepatobiliary & Pancreatic Diseases International
- Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
- (2018) Mohamed E. Salem et al. MOLECULAR CANCER RESEARCH
- Therapeutic developments in pancreatic cancer: current and future perspectives
- (2018) John P. Neoptolemos et al. Nature Reviews Gastroenterology & Hepatology
- Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions
- (2018) Yifan Wang et al. Frontiers in Pharmacology
- New Insights Into the Regulation of γδ T Cells by BTN3A and Other BTN/BTNL in Tumor Immunity
- (2018) Juan-Luis Blazquez et al. Frontiers in Immunology
- Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
- (2018) Deepak Raj et al. GUT
- The Potential of CAR T Cell Therapy in Pancreatic Cancer
- (2018) Mehmet Akce et al. Frontiers in Immunology
- Cytokines in clinical cancer immunotherapy
- (2018) Pedro Berraondo et al. BRITISH JOURNAL OF CANCER
- Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
- (2017) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer
- (2017) Shikhar Mehrotra et al. Journal of Hematology & Oncology
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy
- (2017) Seung Tae Kim et al. Oncotarget
- Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study
- (2016) Nobuaki Suzuki et al. CANCER SCIENCE
- Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
- (2016) Yaqing Zhang et al. GUT
- Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients
- (2016) Motoki Miyazawa et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
- (2016) Timothy M Nywening et al. LANCET ONCOLOGY
- Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer
- (2016) Benjamin Herzberg et al. ONCOLOGIST
- Prognostic value of PDL1 expression in pancreatic cancer
- (2016) David J. Birnbaum et al. Oncotarget
- CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer
- (2016) Katelyn T. Byrne et al. Cell Reports
- Pancreatic cancer
- (2016) Jorg Kleeff et al. Nature Reviews Disease Primers
- KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
- (2016) Daniel Zeitouni et al. Cancers
- Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
- (2016) Peter Bailey et al. Scientific Reports
- Microsatellite instability: an update
- (2015) Hiroyuki Yamamoto et al. ARCHIVES OF TOXICOLOGY
- Systemic Immune Activity Predicts Overall Survival in Treatment-Nai ve Patients with Metastatic Pancreatic Cancer
- (2015) M. R. Farren et al. CLINICAL CANCER RESEARCH
- The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
- (2015) Daniela Angela Covino et al. CURRENT DRUG TARGETS
- Stromal biology and therapy in pancreatic cancer: a changing paradigm
- (2015) Albrecht Neesse et al. GUT
- Phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer: Clinical update on long term survival and biomarker correlates to overall survival.
- (2015) Chan Whiting et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Pancreatic cancer: Update on immunotherapies and algenpantucel-L
- (2015) Kinsey A. McCormick et al. Human Vaccines & Immunotherapeutics
- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
- (2014) M. Aglietta et al. ANNALS OF ONCOLOGY
- Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity
- (2014) Jason W. Griffith et al. Annual Review of Immunology
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
- (2014) Gary Middleton et al. LANCET ONCOLOGY
- Entering the mainstream of cancer treatment
- (2014) Steven A. Rosenberg Nature Reviews Clinical Oncology
- Mechanism of Action of Immunotherapy
- (2014) Mary L. Disis SEMINARS IN ONCOLOGY
- The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer
- (2014) Yan Chen et al. OncoTargets and Therapy
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Exomics and immunogenics
- (2014) Stéphane Champiat et al. OncoImmunology
- Treg and CTLA-4: Two intertwining pathways to immune tolerance
- (2013) Lucy S.K. Walker JOURNAL OF AUTOIMMUNITY
- Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
- (2013) Dung T. Le et al. JOURNAL OF IMMUNOTHERAPY
- Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer
- (2013) Shingo Asahara et al. Journal of Translational Medicine
- Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study
- (2012) Jeffrey M. Hardacre et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma
- (2011) Lutz Eric et al. ANNALS OF SURGERY
- Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine
- (2010) Ghassan K. Abou-Alfa et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Surgical Implication of Micrometastasis for Pancreatic Cancer
- (2010) Masato Kayahara et al. PANCREAS
- Surgery induced immunosuppression
- (2010) Brian V. Hogan et al. SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND
- Clinical Significance of B7-H1 and B7-1 Expressions in Pancreatic Carcinoma
- (2010) Liancai Wang et al. WORLD JOURNAL OF SURGERY
- Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
- (2009) Patrice Dubreuil et al. PLoS One
- Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer
- (2008) Martin Loos et al. CANCER LETTERS
- B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression
- (2008) Lei Geng et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started